N-acetylcysteine inhibits IL-8 and MMP-9 release and ICAM-1 expression by bronchoalveolar cells from interstitial lung disease patients

Pharmacological Reports

Volumn 62, Issue 1, 2010, Pages 131-138

  Radomska Leśniewska, Dorota M ^a   Skopińska Rózewska, Ewa ^a   Jankowska Steifer, Ewa ^a   Sobiecka, Małgorzata ^b   Sadowska, Anna M ^c   Hevelke, Agata ^a   Malejczyk, Jacek ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b NATIONAL TUBERCULOSIS AND LUNG DISEASES RESEARCH INSTITUTE   (Poland)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Bronchoalveolar lavage; Intercellular adhesion molecule 1; Interleukin 8; Interstitial lung diseases; Matrix metalloproteinase; N acetylcysteine

Indexed keywords

ACETYLCYSTEINE; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL COUNT; CELL VIABILITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; DRUG EFFICACY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROSING ALVEOLITIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLUS CELL; LUNG LAVAGE; LUNG SARCOIDOSIS; LYMPHOCYTE; MACROPHAGE; MALE; PROTEIN EXPRESSION; REGULATORY MECHANISM;

EID: 77950829907     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(10)70250-4     Document Type: Article

References (30)

1. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. This joint statement of the American Thoracic Society (ATS) and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by ERS Executive Comittee, June 2001. Am J Respir Crit Care Med, 2002, 165, 277-304.
2. Antoniou KM, Tzouvelekis A, Alexandrakis MG, Sfiridaki K, Tsiligiani I, Rachiotis G, Tzanakis N et al.: Different angiogenic activity in pulmonary sarcoidosis and idiopathic pulmonary fibrosis. Chest, 2006, 130, 982-988.
3. Ask K, Martin G, Kolb M, Gauldie J: Targeting genes for treatment in idiopathic pulmonary fibrosis. Proc Am Thor Soc, 2006, 3, 389-393.
4. Atkinson JJ, Senior RM: Matrix metalloproteinase-9 in lung remodeling. Am J Respir Cell Mol Biol, 2003, 28, 12-14.
5. Behr J: Novel aspects of treatment for interstitial lung diseases. In: Diffuse Parenchymal Lung Disease. Eds. Costabel U, du Bois RM JJ, Prog Respir Res Basel, Karger, 2007, 36, 117-126.
6. Car BD, Meloni F, Luisetti M, Semenzato G, GialdroniGrassi G, Waltz A: Elevated IL-8 and MCP-1 in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Crit Care Med, 1994, 149, 655-659.
7. Dekhuijzen PRN: Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J, 2004, 23, 629-636.
8. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W et al.: IFIGENIA Study Group: High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med, 2005, 353, 22292-22242.
9. Girgis RE, Basha MA, Maliarik M: Cytokines in bronchoalveolar lavage fluid of patients with active pulmonary sarcoidosis. Am J Respir Crit Care Med, 1995, 152, 71-75.
10. Henry MT, McMahon K, Mackarel AJ, Prikk K, Sorsa T, Maisi P, Sepper R et al.: Matrix metalloproteinases and tissue inhibitor of metalloproteinase-1 in sarcoidosis and IPF. Eur Respir J, 2002, 20, 1220-1227.
11. Hunninghake GW: Antioxidant therapy for idiopathic pulmonary fibrosis. N Engl J Med, 2005, 353, 2285-2287.
12. Ishii Y, Kitamura S: Elevated level of soluble ICAM in serum and BAL fluid in patients with active sarcoidosis. Chest, 1995, 107, 1636-1640.
13. John M, Oltmans U, Fietze I, Witt C, Jung K: Increased production of matrix metalloproteinase-2 in alveolar macrophages and regulation by interleukin-10 in patients with acute pulmonary sarcoidosis. Exp Lung Res, 2002, 28, 55-68.
14. Kim KA, Lim YS, Kim KM, Yoon JH, Lee HS: 15d-Deoxy-prostaglandin J modulates collagen type I synthesis in human hepatic stellate cells by inducing oxidative stress. Prostaglandins Leukot Essent Fatty Acids, 2005,73,361-367.
15. Kinula VL, Fattman ChL, Tan RJ, Oury TD: Oxidative stress in pulmonary fibrosis. Am J Respir Crit Care Med, 2005,172,417-422.
16. Lagente V, Manoury B, Nenan S, Le Quement C, MartinChouly C, Boichot E: Role of matrix metalloproteinases in the development of airway inflammation and remodeling. Brazil J Med Biol Res, 2005, 38, 1521-1530.
17. Lappas M, Permezel M, Rice G: N-acetylcysteine inhibits phospholipid metabolizm, proinflammatory cytokine release, protease activity, and nuclear factorB deoxyribonucleic acid-binding acivity in human fetal membranes in vitro. J Clin Endocrinol Metabol, 2003, 88, 1723-1729.
18. Maher TM, Wells AU, Laurent GJ: Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Resp J, 2007, 30, 835-839.
19. Paterson RL, Galley HF, Webster NR: Te effect of of N-acetylcysteine on nuclear factorB activation, interleukin-6, interleukin-8 and intercellular adhesion molecule-1 expression in patients with sepsis. Crit Care Med, 2003, 31, 2574-2578.
20. Radomska-Leśniewska DM, Sadowska AM, van Overveld FJ, Demkow U, Zieliński J, De Backer WA: Influence of N-acetylcysteine on ICAM-1 expression and IL-8 release from endothelial and epithelial cells. J Physiol Pharmacol, 2006, 57, 325-334.
21. Radomska-Leśniewska DM, Sobiecka M, Chorostowska-Wynimko J, Białas-Chromiec B, Kuś J, Wesołowski S, Skopińska-Rózewska E: Relationship between IL-8, IL-10, and MMP-9 level and morphological pattern of BAL fluid in interstitial lung diseases patients. Centr Eur J Immunol, 2003, 28, 155-159.
22. Roman J, Galis Z: Sarkoidosis: a mystery tale of inflammation, tissue remodeling and matrix metalloproteinases. Hum Pathol, 2002, 33, 1155-1157.
23. Sadowska AM, Manuel-Y-Keenoy B, De Backer WA: Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review. Pulm Pharmacol Ther, 2007, 20, 9-22.
24. Silvestri M, Serpero L, Petecchia L, Sabatini F, Cerasoli F Jr, Rossi GA: Cytokine-activated bronchial epithelial cell pro-inflammatory functions are downregulated in vitro by ciclesonide. Pulm Pharmacol Ther, 2006, 19, 210-217.
25. Sukurada S, Kato T, Okamoto T: Induction of cytokines and ICAM-1 by proinflammatory cytokines i primary rheumatoid synovial fibroblasts and inhibition by N-acetyl-L-cysteine and aspirin. Intern Immunol, 1996, 8, 1483-1493.
26. Tong, Z, Dai H, Chen B, Abdoch Z, Guzman J, Costabel U: Inhibition of cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline: comparison with dexamethasone. Chest, 2003, 124, 1526-1532.
27. Vasallo R: Recent advances in interstitial lung diseases research. Malta Med J, 2006, 18, 12-17.
28. Walter N, Cllard HR, Kig TE Jr: Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc Am Thor Soc, 2006, 3, 330-338.
29. Wuyts WA, Vanaudenaerde BM, Dupond LJ, Demets MG, Verleden GM: N-acetylcysteine reduced chemokine released via inhibition of p38 MAPK in human airway smooth muscle cell. Eur Respir J, 2003, 22, 43-49.
30. Ye Q, Chen B, Tong Z, Nakamura S, Sarria R, Costabel U, Guzman J: Thalidomide reduces IL-18, IL-8 and TNFrelease from alveolar macrophages in interstitial lung disease. Eur Respir J, 2006, 28, 824-831.